When was Celystra founded?

Celystra was founded in 2026 and raised its 1st funding round within a year of its incorporation.

Where is Celystra located?

Celystra is headquartered in Montreal, Canada.

Is Celystra a funded company?

Celystra is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on May 05, 2026.

When was the latest funding round of Celystra?

Celystra's latest funding was a $***** Series B round on May 05, 2026, with participation from 2 investors. Its primary sector is Rare Diseases. In Canada, the Rare Diseases sector has seen $59.7M in funding in 2026 to date.

Where does Celystra rank among its competitors?

Celystra ranks 9th amongst 17 active competitors, of which 5 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Celystra, which secured $20M in May, 2026.

Who are the top competitors of Celystra?

Celystra's top competitors include Ascelia, Navigene and Blueprint Genetics. Among them, Celystra secured the most recent funding round in May, 2026.

Celystra - 2026 Company Profile, Funding & Competitors

Celystra is a series B company based in Montreal (Canada), founded in 2026. It operates as a Provider of pharmaceutical treatments for patients with rare medical conditions. Celystra has raised $20M in funding. The company has 17 active competitors, including 5 funded and 6 that have exited. Its top competitors include companies like Ascelia, Navigene and Blueprint Genetics.

Company Details

Provider of pharmaceutical treatments for patients with rare medical conditions. This entity identifies and acquires medical therapies developed by other organizations to increase availability for individuals suffering from specific genetic disorders. The business focuses on securing access to medications that address unmet health needs.

Website: www.celystrapharma.com/
Email ID: *****@celystrapharma.com

Key Metrics

Founded Year

2026

Location

Montreal, Canada

Stage

Series B

Total Funding

$20M in 1 round

Latest Funding Round

Series B, May 05, 2026, $*****

Investors

Invest Quebec & 1 more

Ranked

9^th among 17 active competitors

Similar Companies

Ascelia & 16 more

View Celystra's full profile

Celystra has raised a total funding of $20M over 1 round. Its latest funding round was a Series B round on May 05, 2026 for $*****. 2 investors participated in its latest round. Celystra has 2 institutional investors.

Here is the list of recent funding rounds of Celystra:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 05, 2026	4783377	Series B	2021401	1014771	4205728	4106816

Access funding benchmarks and valuations. Sign up today!

View details of Celystra's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Celystra include Ascelia, Navigene and Blueprint Genetics. Here is the list of Top 10 competitors of Celystra, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ascelia 2000, Malmo (Sweden), Public	Developer of orphan drugs for treatment and diagnostics solutions	$6.92M	Eiffel Investment Group, Sunstone & 3 others	55/100
2nd	Navigene 2012, Mumbai (India), Seed	Provider of diagnosing genetic medical conditions and recommending preventive care	$838K	SAVA group, Ecosystem Ventures & 30 others	53/100
3rd	Blueprint Genetics 2012, Espoo (Finland), Acquired	Provider of genetic diagnostics and clinical interpretation for hereditary diseases	$26.2M	Inventure, MTIP & 4 others	51/100
4th	3billion 2016, Seoul (South Korea), Public	Provider of AI-driven clinical diagnostic testing platform for rare genetics disease	$25.7M	Magna, Korea Development Bank Europe & 13 others	46/100
5th	FDNA 2010, Herzliya (Israel), Funding Raised	Developer of neurogenetic search and reference solution for the detection of facial dysmorphic features	-	Nacre Capital, Clal Biotechnology Industries	44/100
6th	Imegen 2009, Paterna (Spain), Acquired	Provider of genetic tests for the detection of various disease conditions	-	Europa, Qualitas Equity Partners & 1 others	37/100
7th	Vgenomics 2021, Noida (India), Seed	Developer of diagnostic and therapeutic solutions for inborn diseases	-	Mumbai Angels, O2 Angels Network & 3 others	37/100
8th	Metafora Biosystems 2011, Paris (France), Funding Raised	Provider of diagnostic tests and reagents for research	-	EIC Fund, Europa & 1 others	35/100
9th	Celystra 2026, Montreal (Canada), Series B	Provider of pharmaceutical treatments for patients with rare medical conditions	$20M	Invest Quebec, Credit Mutuel Equity	33/100
10th	NeoGen Labs 2006, Bengaluru (India), Seed	Neonatal diagnostic solutions for the detection of inborn errors of metabolism	$453K	Bhagwati Group & 18 others	32/100